Emergent BioSolutions Inc. (EBS)
USD 8.16
(-7.17%)
USD 8.16
(-7.17%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 765.8 Million USD | 0.34% |
| 2022 | 763.2 Million USD | 188.11% |
| 2021 | 264.9 Million USD | 4.5% |
| 2020 | 253.5 Million USD | -60.61% |
| 2019 | 643.5 Million USD | -5.7% |
| 2018 | 682.4 Million USD | 513.99% |
| 2017 | -164.83 Million USD | -4721.15% |
| 2016 | -3.41 Million USD | 94.28% |
| 2015 | -59.79 Million USD | -102.7% |
| 2014 | -29.49 Million USD | 74.86% |
| 2013 | -117.33 Million USD | -48.73% |
| 2012 | -78.89 Million USD | 6.58% |
| 2011 | -84.44 Million USD | 30.55% |
| 2010 | -121.59 Million USD | -226.81% |
| 2009 | -37.2 Million USD | -8.5% |
| 2008 | -34.29 Million USD | 28.26% |
| 2007 | -47.79 Million USD | -42.05% |
| 2006 | -33.64 Million USD | -37.99% |
| 2005 | -24.38 Million USD | -503.31% |
| 2004 | 6.04 Million USD | 0.0% |
| 2002 | -4.89 Million USD | -117.5% |
| 2001 | 27.94 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 805.8 Million USD | -4.44% |
| 2024 Q1 | 843.2 Million USD | 10.11% |
| 2023 Q1 | 968.2 Million USD | 26.86% |
| 2023 Q3 | 325.8 Million USD | -60.0% |
| 2023 Q2 | 814.6 Million USD | -15.86% |
| 2023 FY | 765.8 Million USD | 0.34% |
| 2023 Q4 | 765.8 Million USD | 135.05% |
| 2022 FY | 763.2 Million USD | 188.11% |
| 2022 Q2 | 467.1 Million USD | 17.57% |
| 2022 Q1 | 397.3 Million USD | 49.98% |
| 2022 Q3 | 812.4 Million USD | 73.92% |
| 2022 Q4 | 763.2 Million USD | -6.06% |
| 2021 Q2 | 406.5 Million USD | 30.58% |
| 2021 Q1 | 311.3 Million USD | 22.8% |
| 2021 Q4 | 264.9 Million USD | -40.49% |
| 2021 Q3 | 445.1 Million USD | 9.5% |
| 2021 FY | 264.9 Million USD | 4.5% |
| 2020 Q4 | 253.5 Million USD | -45.41% |
| 2020 FY | 253.5 Million USD | -60.61% |
| 2020 Q1 | 607.7 Million USD | -5.56% |
| 2020 Q2 | 518.4 Million USD | -14.69% |
| 2020 Q3 | 464.4 Million USD | -10.42% |
| 2019 Q2 | 663.1 Million USD | 9.55% |
| 2019 Q1 | 605.3 Million USD | -11.3% |
| 2019 FY | 643.5 Million USD | -5.7% |
| 2019 Q3 | 684.2 Million USD | 3.18% |
| 2019 Q4 | 643.5 Million USD | -5.95% |
| 2018 FY | 682.4 Million USD | 513.99% |
| 2018 Q1 | -150.13 Million USD | 8.92% |
| 2018 Q2 | -176.75 Million USD | -17.73% |
| 2018 Q4 | 682.4 Million USD | 309.41% |
| 2018 Q3 | -325.86 Million USD | -84.36% |
| 2017 Q4 | -164.83 Million USD | -79.17% |
| 2017 Q2 | -66.93 Million USD | -207.38% |
| 2017 FY | -164.83 Million USD | -4721.15% |
| 2017 Q1 | -21.77 Million USD | -536.91% |
| 2017 Q3 | -91.99 Million USD | -37.44% |
| 2016 Q3 | -31.13 Million USD | 63.79% |
| 2016 FY | -3.41 Million USD | 94.28% |
| 2016 Q4 | -3.41 Million USD | 89.02% |
| 2016 Q2 | -86 Million USD | 8.34% |
| 2016 Q1 | -93.82 Million USD | -56.91% |
| 2015 Q4 | -59.79 Million USD | -7.32% |
| 2015 Q2 | 38.15 Million USD | 10.65% |
| 2015 Q1 | 34.48 Million USD | 216.9% |
| 2015 FY | -59.79 Million USD | -102.7% |
| 2015 Q3 | -55.71 Million USD | -246.02% |
| 2014 Q2 | 82.87 Million USD | -8.72% |
| 2014 FY | -29.49 Million USD | 74.86% |
| 2014 Q3 | 8.75 Million USD | -89.44% |
| 2014 Q1 | 90.78 Million USD | 177.37% |
| 2014 Q4 | -29.49 Million USD | -437.09% |
| 2013 Q1 | -68.58 Million USD | 13.07% |
| 2013 Q3 | -113.13 Million USD | -18.22% |
| 2013 Q2 | -95.7 Million USD | -39.55% |
| 2013 Q4 | -117.33 Million USD | -3.71% |
| 2013 FY | -117.33 Million USD | -48.73% |
| 2012 FY | -78.89 Million USD | 6.58% |
| 2012 Q2 | -99.64 Million USD | -11.27% |
| 2012 Q3 | -134.88 Million USD | -35.37% |
| 2012 Q4 | -78.89 Million USD | 41.51% |
| 2012 Q1 | -89.55 Million USD | -6.05% |
| 2011 Q2 | -82.79 Million USD | 8.36% |
| 2011 FY | -84.44 Million USD | 30.55% |
| 2011 Q1 | -90.34 Million USD | 25.7% |
| 2011 Q3 | -71.55 Million USD | 13.57% |
| 2011 Q4 | -84.44 Million USD | -18.02% |
| 2010 FY | -121.59 Million USD | -226.81% |
| 2010 Q2 | -53.09 Million USD | -3.26% |
| 2010 Q1 | -51.42 Million USD | -38.21% |
| 2010 Q4 | -121.59 Million USD | -18.09% |
| 2010 Q3 | -102.96 Million USD | -93.92% |
| 2009 Q1 | -4.85 Million USD | 85.84% |
| 2009 Q4 | -37.2 Million USD | 53.02% |
| 2009 FY | -37.2 Million USD | -8.5% |
| 2009 Q3 | -79.19 Million USD | -68.67% |
| 2009 Q2 | -46.95 Million USD | -866.85% |
| 2008 Q3 | -46.29 Million USD | -87.48% |
| 2008 Q2 | -24.69 Million USD | 24.06% |
| 2008 Q1 | -32.52 Million USD | 31.96% |
| 2008 FY | -34.29 Million USD | 28.26% |
| 2008 Q4 | -34.29 Million USD | 25.94% |
| 2007 Q4 | -47.79 Million USD | -310.49% |
| 2007 FY | -47.79 Million USD | -42.05% |
| 2007 Q2 | -1.36 Million USD | 96.02% |
| 2007 Q1 | -34.26 Million USD | -1.82% |
| 2007 Q3 | 22.7 Million USD | 1765.96% |
| 2006 FY | -33.64 Million USD | -37.99% |
| 2006 Q4 | -33.64 Million USD | -303.1% |
| 2006 Q3 | 16.56 Million USD | 0.0% |
| 2005 Q4 | -24.38 Million USD | 0.0% |
| 2005 FY | -24.38 Million USD | -503.31% |
| 2004 FY | 6.04 Million USD | 0.0% |
| 2004 Q4 | 6.04 Million USD | 0.0% |
| 2002 FY | -4.89 Million USD | -117.5% |
| 2001 Q4 | -544.5 Million USD | 0.0% |
| 2001 FY | 27.94 Million USD | 0.0% |
| 2000 Q4 | 314.7 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 2.65 Billion USD | 71.199% |
| Bausch Health Companies Inc. | 21.44 Billion USD | 96.428% |
| Catalent, Inc. | 4.69 Billion USD | 83.703% |
| Elanco Animal Health Incorporated | 5.42 Billion USD | 85.876% |
| Perrigo Company plc | 3.32 Billion USD | 76.948% |
| Teva Pharmaceutical Industries Limited | 16.92 Billion USD | 95.476% |
| Zoetis Inc. | 4.76 Billion USD | 83.919% |